Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice Tsang Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015

Cited by 636 works. doi:10.1016/s1470-2045(15)00488-x

Authors

References